Evaluating the safety and efficacy of a Unani formulation in Psoriasis

A Randomized, Parallel Group, Open Label, Active Controlled Clinical Study to evaluate the Safety and Efficacy of Majoon-e-Shahtara and Raughan Barzad in the Management of Taqashshur al-Jild(Psoriasis) - NA

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/10/058549

Enrollment

Registered

2023-10-12

Start date

Unknown

Completion date

Unknown

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L409- Psoriasis, unspecified

Interventions

Intervention1: 1.Majoon-e-Shahtara(Oral) 2.Raughan Barzad(Topical): 1.Majoon-e-Shahtara Dosage form:Majoon(semisolid paste) Dose: 5gms BD Mode of administration:oral Composition of Majoon-e-Shahtara

Eligibility

Inclusion criteria

Inclusion criteria: 1Patients of any sex aged between 18-60 years of age 2Patients clinically diagnosed with Taqashshur al-Jild (Psoriasis) 3Psoriasis area severity index (PASI) =10%

Exclusion criteria

Exclusion criteria: 1Patients aged 60 years 2Known cases of Diabetes 3Pregnant or Lactating Women 4Significant Pulmonary/Cardiovascular/Hepato-renal Dysfunction 5Known cases of Immunocompromised states (HIV/ AIDS, etc.)/ Malignancies 6Patient not willing to attend treatment schedule regularly 7Patients with Psoriatic arthritis 8Erythrodermic psoriasis

Design outcomes

Primary

Measure	Time frame
Reduction in mean PASI from baselineTimepoint: 84 DAYS	—

Secondary

Measure	Time frame
Improvement in DLQI from baselineTimepoint: 84 Days;Improvement in IGA from baselineTimepoint: 84 Days	—

Countries

India

Contacts

Public ContactDr Sana Anjum

National Research Institute of Unani Medicine for Skin Disorders

aarzu763@gmail.com9032519286

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026